No information is available on the clinical use of necitumumab during breastfeeding. Because necitumumab is a large protein molecule with a molecular weight of 145,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3] However, the manufacturer recommends that women receiving necitumumab should not breastfeed during therapy or for 3 months following the final dose.
关于奈昔妥珠单抗在母乳喂养期间的临床应用尚无可用信息。由于奈昔妥珠单抗是一种分子量为145,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收可能极少。[2]产后至少等待2周再恢复治疗可能会将药物转移至婴儿的情况降至最低。[3]然而，制造商建议接受奈昔妥珠单抗治疗的女性在治疗期间及最后一剂后3个月内不应进行母乳喂养。
Zotero 插件